{
  "id": 16890068,
  "title": "Why is Boston Scientific stock sliding today?",
  "url": "https://urgent.news/2026/10/28/why-is-boston-scientific-stock-sliding-today",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-28T11:22:47.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/why-is-boston-scientific-stock-sliding-today-93CH-4978603"
  },
  "original_language": "en",
  "account": "Boston Scientific's stock is currently plummeting 3.6% in pre-market trading, trading at $43.42 after the company released its third-quarter 2026 results. The medical device company's earnings missed expectations, posting adjusted EPS of $0.73, which fell $0.02 short of the $0.75 analyst consensus. While revenue of $5.14 billion exceeded estimates of $5.12 billion, it marked a 1.5% year-over-year increase.\n\nThe most significant concern came from the company's guidance. Boston Scientific lowered its Q4 2026 adjusted EPS guidance to $0.77–$0.79, significantly below the $0.83 consensus. Additionally, the full-year 2026 adjusted EPS guidance was revised to $3.16–$3.18, a substantial drop from the previous range of $3.28–$3.32. This guidance reduction, coupled with the company's projection of Q4 net sales decline of 1%–3% year-over-year, has left investors shaken.\n\nThe cyberattack that occurred on August 25 and disrupted manufacturing, order processing, and global shipments remains a major factor in the stock's decline. The company had already revised its 2026 forecasts in September, but the broader market conditions are not providing much relief. The S&P 500 is barely positive, with a gain of just 0.1%, while the Dow Jones is slightly down. These macro factors provide no cushioning for the stock-specific selling pressure.\n\nLong-standing issues, such as competitive pressure on the FARAPULSE electrophysiology franchise and softer demand for the WATCHMAN device, continue to weigh on sentiment. The stock is now near its 52-week low of $41.38. The earnings miss, steep guidance cut, and lingering uncertainty about full operational recovery from the cyberattack have collectively pushed BSX lower in pre-market trading as investors reassess the company's near-term earnings potential heading into the final quarter of 2026.",
  "summary": null,
  "key_points": [
    "Boston Scientific's Q3 2026 earnings missed analyst consensus",
    "Company lowered Q4 2026 EPS guidance to $0.77–$0.79",
    "Cyberattack on August 25 disrupted operations and sales"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}